B of A Securities initiated coverage on Vanda Pharmaceuticals with a new price target
$VNDA
Biotechnology: Pharmaceutical Preparations
Health Care
B of A Securities initiated coverage of Vanda Pharmaceuticals with a rating of Buy and set a new price target of $22.00